Literature DB >> 6391371

Renal disposition of ceftazidime illustrated by interferences by probenecid, furosemide, and indomethacin in rabbits.

C Carbon, F Dromer, N Brion, A C Cremieux, A Contrepois.   

Abstract

Excretion of ceftazidime (C), a new cephalosporin antibiotic, has been reported to occur unexpectedly through glomerular filtration only, without being significantly affected by probenecid. We investigated renal tubular disposition of C in rabbits by calculating its rates of fractional excretion, net tubular secretion, and absolute excretion. During continuous intravenous infusion of C, 3 mg of furosemide (F), 15 mg of probenecid (P), or 2 mg of indomethacin (I) per kg was injected intravenously as a bolus. Equilibrium dialysis showed that the percentage of C bound to serum proteins (14 +/- 5%) was not altered by F, P, or I. Fractional excretion of C was 94 +/- 22, 65 +/- 21, 182 +/- 36, and 98 +/- 3% for the drug given alone and after injection of F, P, and I, respectively. For 15 min after P injection, we observed net tubular secretion of C (404 +/- 276 micrograms/min). The C absolute excretion rate was significantly reduced by I compared with the absolute excretion rate for the control (405 +/- 104 versus 696 +/- 157 micrograms/min). We conclude that (i) C undergoes bidirectional transport in the nephron, revealed by the effects of F and P, with a nil net C balance; (ii) F and P have opposite unexpected effects on tubular handling of C, possibly due to competition for C secretion processes; (iii) I reduces C excretion solely by decreasing its glomerular-filtered load; and (iv) tubular handling of C differs from that of previously studied cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6391371      PMCID: PMC176173          DOI: 10.1128/AAC.26.3.373

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Animal scale-up.

Authors:  R L Dedrick
Journal:  J Pharmacokinet Biopharm       Date:  1973-10

2.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

3.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

4.  Clinical Pharmacokinetics of indomethacin.

Authors:  L Helleberg
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

5.  Effects of phenylbutazone on extravascular diffusion, protein binding and urinary excretion of cefazolin in rabbits.

Authors:  C Carbon; A Contrepois; Y Nivoche; M Grandjean; S Decourt; N P Chau
Journal:  J Pharmacol Exp Ther       Date:  1981-08       Impact factor: 4.030

Review 6.  Clinical pharmacokinetics of probenecid.

Authors:  R F Cunningham; Z H Israili; P G Dayton
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

7.  Modulation by prostaglandin synthesis inhibitors of the action of exogenous angiotensin II on glomerular ultrafiltration in the rat.

Authors:  C Baylis; B M Brenner
Journal:  Circ Res       Date:  1978-12       Impact factor: 17.367

8.  Probenecid: an unexplained effect on cephalosporin pharmacology.

Authors:  P G Welling; S Dean; A Selen; M J Kendall; R Wise
Journal:  Br J Clin Pharmacol       Date:  1979-11       Impact factor: 4.335

9.  Effects of furosemide on extravascular diffusion, protein binding and urinary excretion of cephalosporins and aminoglycosides in rabbits.

Authors:  C Carbon; A Contrepois; A M Vigneron; S Lamotte-Barrillon
Journal:  J Pharmacol Exp Ther       Date:  1980-06       Impact factor: 4.030

10.  Penetration of cefazolin, cephaloridine, and cefamandole into interstitial fluid in rabbits.

Authors:  C Carbon; A Contrepois; N Brion; S Lamotte-Barrillon
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

View more
  8 in total

1.  Reduction in biliary excretion of ceftriaxone by diclofenac in rabbits.

Authors:  M Merle-Melet; N Seta; R Farinotti; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Urinary alanine-aminopeptidase (AAP) excretion in patients with urinary tract infection treated with ceftazidime (CAZ) or cefotaxime (CTX) plus tobramycin (TOB).

Authors:  A Wiecek; F Kokot; W Grzeszczak
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

3.  Value of antibiotic levels in serum and cardiac vegetations for predicting antibacterial effect of ceftriaxone in experimental Escherichia coli endocarditis.

Authors:  V Joly; B Pangon; J M Vallois; L Abel; N Brion; A Bure; N P Chau; A Contrepois; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

4.  Effects of urinary pH on renal interactions between probenecid and cefsulodin in rabbits.

Authors:  F Dromer; A Contrepois; N Brion; C Klein; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

5.  Ceftriaxone diffusion from blood to aqueous humour in man.

Authors:  D Gobeaux; L Ambart; J L Couderc; P H Renard; B De Charnace; F Lokiec
Journal:  Br J Ophthalmol       Date:  1989-07       Impact factor: 4.638

6.  Effects of diclofenac on ceftriaxone pharmacokinetics in humans.

Authors:  M Merle-Melet; L Bresler; F Lokiec; C Dopff; P Boissel; J B Dureux
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 7.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

Review 8.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.